Anika Therapeutics Announces Date of First-Quarter 2013 Financial Results
BEDFORD, Mass. -- April 5, 2013
Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that it plans to issue
its first-quarter 2013 financial results after the close of the market on
Wednesday, May 1, 2013. The company plans to hold a conference call the next
day, Thursday, May 2 at 9:00 a.m. ET to discuss its financial results,
business highlights and outlook. In addition, the company will answer
questions concerning business and financial developments and trends, and other
business and financial matters affecting the company, some of the responses to
which may contain information that has not been previously disclosed.
To listen to the conference call, dial 866-825-1709 (international callers
dial 617-213-8060) and use the passcode 28203075. In addition, the call will
be available through a live audio webcast in the "Investor Relations" section
of Anika’s website, www.anikatherapeutics.com. An accompanying slide
presentation also can be accessed via the Anika Therapeutics website. The call
will be archived and accessible on the same website shortly after its
The webcast also is being distributed through the Thomson StreetEvents
Network. Individual investors can listen to the call at www.earnings.com,
Thomson's individual investor portal, powered by StreetEvents. Institutional
investors can access the call via Thomson StreetEvents (www.streetevents.com),
a password-protected event management site.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
manufactures and commercializes therapeutic products for tissue protection,
healing, and repair. These products are based on hyaluronic acid (HA), a
naturally occurring, biocompatible polymer found throughout the body. Anika’s
products range from orthopedic/joint health solutions led by Orthovisc^®, a
treatment for osteoarthritis of the knee; to surgical aids in the
anti-adhesion and ophthalmic fields. The company also offers aesthetic dermal
fillers for the correction of facial wrinkles. Anika’s Italian subsidiary,
Anika Therapeutics, S.r.l., provides complementary HA products in
orthopedic/joint health and anti-adhesion, as well as therapeutics in areas
such as advanced wound treatment and ear, nose and throat care. Its
regenerative technology advances Anika’s vision to offer therapeutic products
that go beyond pain relief to protect and restore damaged tissue.
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., President and CEO or
Sylvia Cheung, CFO
Press spacebar to pause and continue. Press esc to stop.